S& P 500 hits all time highs U.S.-Japan trade deal optimism
ROCKVILLE, Md. - MaxCyte, Inc. (Nasdaq:MXCT; LSE:MXCT) announced that all resolutions were passed at its Annual General Meeting held Wednesday, including the cancellation of the company’s admission to trading on London’s AIM market.
The cell-engineering technology company will delist from AIM on June 26, 2025, with the last day of trading on that exchange set for June 25. Following the delisting, MaxCyte’s common stock will continue to trade exclusively on the Nasdaq Global Select Market under the ticker symbol MXCT.
"I would like to thank our shareholders for their support since the Company’s AIM listing in 2016," said Maher Masoud, President and CEO of MaxCyte, in a statement included in the press release. "The belief and continued commitment from our U.K. investors in our vision of enabling cell and gene therapies allowed us to have the foundation to become the only cell-engineering technology used in the engineering of a commercial non-viral gene edited product."
MaxCyte provides platform technologies designed to advance the development and commercialization of cell therapeutics. The company has maintained dual listings since its initial AIM debut in 2016.
The full text of the resolutions passed at the Annual General Meeting was published and posted to stockholders on April 28, 2025, according to the company’s statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.